Case Report

Annals of Nuclear Medicine

, Volume 22, Issue 5, pp 429-432

Early relapse in a patient with Hodgkin’s disease and negative interim FDG-PET

  • Stefano FantiAffiliated withUnità Operativa di Medicina Nucleare, Padiglione 30, Azienda Ospedaliero Universitaria di Bologna, Policlinico S. Orsola-Malpighi Email author 
  • , Paolo CastellucciAffiliated withUnità Operativa di Medicina Nucleare, Padiglione 30, Azienda Ospedaliero Universitaria di Bologna, Policlinico S. Orsola-Malpighi
  • , Vittorio StefoniAffiliated withUnità Operativa di Ematologia, Istituto “Seragnoli”, Policlinico S. Orsola-Malpighi
  • , Cristina NanniAffiliated withUnità Operativa di Medicina Nucleare, Padiglione 30, Azienda Ospedaliero Universitaria di Bologna, Policlinico S. Orsola-Malpighi
  • , Monica TaniAffiliated withUnità Operativa di Ematologia, Istituto “Seragnoli”, Policlinico S. Orsola-Malpighi
  • , Domenico RubelloAffiliated withUnità Operativa di Medicina Nucleare, Ospedale S. Maria della Misericordia
  • , Valentina AmbrosiniAffiliated withUnità Operativa di Medicina Nucleare, Padiglione 30, Azienda Ospedaliero Universitaria di Bologna, Policlinico S. Orsola-Malpighi
  • , Pier Luigi ZinzaniAffiliated withUnità Operativa di Ematologia, Istituto “Seragnoli”, Policlinico S. Orsola-Malpighi
  • , Roberto FranchiAffiliated withUnità Operativa di Medicina Nucleare, Padiglione 30, Azienda Ospedaliero Universitaria di Bologna, Policlinico S. Orsola-Malpighi

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The role of F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the assessment of lymphoma patients is well established, and PET is routinely used for initial staging, early evaluation of treatment response, and identification of disease relapse. The early evaluation of response to therapy (interim PET) has been reported to be an accurate predictor of progression-free survival, and end-treatment PET has been suggested to be unnecessary if interim PET results are negative. We report on a patient with Hodgkin’s disease with a positive PET scan at presentation and a negative interim PET (carried out after three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine; ABVD). Despite uncomplicated clinical course, end-treatment PET (following six cycles) was positive, showing a very early relapse. For this reason, patient underwent further treatment; however, a complete remission was not obtained, and a poor prognosis is expected. This case testifies the possibility of early relapse of lymphoma even in the case of negative interim PET; it also supports the usefulness of end-treatment PET scan in lymphoma patients.

Keywords

Positron emission tomography Hodgkin’s lymphoma FDG diagnostic use